Non-Alcoholic Fatty Liver (NAFL)

Completed and published in Hepatology. The 6-month prospective, randomized, double-blind, placebo-controlled human clinical trial showed that Basis, at the recommended dose, reduced several markers of liver inflammation in healthy adults with fatty liver. The results also further confirmed that Basis is safe and well tolerated in healthy individuals. 

Next up:

Age-Related Frailty

Initiated at Mayo Clinic, the human clinical trial will evaluate whether Elysium’s proprietary nicotinamide riboside (NR-E) can augment bone, skeletal muscle, and metabolic functions and structure in aging. Estimated primary study completion date of December 2023.

TIME-A

The Translational Initiative to Map Epigenetics in Aging (TIME-A) is a longitudinal, prospective research study that aims to advance our understanding of the connections between epigenetics, lifestyle, demographics, and health and aging. All Index users are eligible to enroll. The study can be found on www.clinicaltrials.gov under the identifier NCT05760547.

Slow Age

Initiated at the University of Copenhagen, the human clinical trial will evaluate the effects of nicotinamide riboside (NR), aerobic exercise, or time-restricted feeding on markers of aging. Estimated study completion date of March 2023.